An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Last updated: November 2, 2007
Sponsor: InterMune
Overall Status: Completed

Phase

2

Condition

Scar Tissue

Idiopathic Pulmonary Fibrosis

Cystic Fibrosis

Treatment

N/A

Clinical Study ID

NCT00052052
GIPF-004
  • Ages 20-79
  • All Genders

Study Summary

Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.

Eligibility Criteria

Inclusion

Male or Female

Idiopathic Pulmonary Fibrosis

20-79 years

Must have participated in the InterMune protocol GIPF-001 study.

Study Design

Total Participants: 210
Study Start date:
September 01, 2002
Estimated Completion Date:
September 30, 2004

Connect with a study center

  • University of Washington Medical Center

    Seattle, Washington 98195
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.